论文部分内容阅读
糖尿病视网膜病变（DR）是糖尿病最为常见和严重的并发症之一，是成年人视力丧失的主要原因。越来越多的证据表明，炎症在DR的发病机制中发挥关键作用，抗炎治疗或许能有效延缓DR的发生和发展。单核细胞趋化蛋白-1 （MCP-1）作为炎症反应过程中一种重要的趋化因子，通过趋化和激活因子、破坏血视网膜屏障、引起视网膜血管病变、激活小胶质细胞等促进DR的发生发展，并与疾病的严重程度相关。随着对MCP-1研究的进一步深入，可能将趋化因子及其受体作为靶细胞，在疾病的早期阶段，通过减少或抑制糖尿病患者MCP-1的产生，从而控制或减缓DR进展，这将为我们预防和治疗DR提供新思路和新方法。“,”Diabetic retinopathy (DR) is one of the most common and serious diabetic complications, which is the main cause of vision loss in adults. The specific vascular and neuropathology mechanism of DR is not clear. It has been demonstrated that Inflammatory reaction might be take effects in the development and progression of DR. Monocyte chemoattractant protein-1 (MCP-1), as an important chemokine in the inflammatory response process, promotes chemotactic and activating factors, destroys the blood-retinal barrier, causes retinal vascular disease, and activates microglia, which is related to the severity of the disease. With further research on MCP-1, it is possible to use chemokines and their receptors as target cells to control or slow down the progression of DR by reducing or inhibiting the production of MCP-1 in diabetic patients in the early stages of the disease. This study can provide new ideas and new methods about preventing and treating DR.